JP7600119B2 - アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体 - Google Patents
アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体 Download PDFInfo
- Publication number
- JP7600119B2 JP7600119B2 JP2021542335A JP2021542335A JP7600119B2 JP 7600119 B2 JP7600119 B2 JP 7600119B2 JP 2021542335 A JP2021542335 A JP 2021542335A JP 2021542335 A JP2021542335 A JP 2021542335A JP 7600119 B2 JP7600119 B2 JP 7600119B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compounds
- group
- spp
- adenosine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19152961 | 2019-01-22 | ||
| EP19152961.9 | 2019-01-22 | ||
| PCT/EP2020/051347 WO2020152132A1 (en) | 2019-01-22 | 2020-01-21 | Thiazolopyridine derivatives as adenosine receptor antagonists |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022524914A JP2022524914A (ja) | 2022-05-11 |
| JP2022524914A5 JP2022524914A5 (https=) | 2023-01-31 |
| JPWO2020152132A5 JPWO2020152132A5 (https=) | 2023-01-31 |
| JP7600119B2 true JP7600119B2 (ja) | 2024-12-16 |
Family
ID=65199346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542335A Active JP7600119B2 (ja) | 2019-01-22 | 2020-01-21 | アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US12344623B2 (https=) |
| EP (1) | EP3914600B1 (https=) |
| JP (1) | JP7600119B2 (https=) |
| KR (1) | KR102891741B1 (https=) |
| CN (1) | CN113939520B (https=) |
| AR (1) | AR117844A1 (https=) |
| AU (1) | AU2020211697B2 (https=) |
| BR (1) | BR112021014406A2 (https=) |
| CA (1) | CA3127284A1 (https=) |
| DK (1) | DK3914600T3 (https=) |
| ES (1) | ES2992081T3 (https=) |
| FI (1) | FI3914600T3 (https=) |
| HR (1) | HRP20241385T1 (https=) |
| HU (1) | HUE068968T2 (https=) |
| IL (1) | IL285024A (https=) |
| LT (1) | LT3914600T (https=) |
| MX (1) | MX2021008510A (https=) |
| PL (1) | PL3914600T3 (https=) |
| PT (1) | PT3914600T (https=) |
| RS (1) | RS66038B1 (https=) |
| SG (1) | SG11202107858WA (https=) |
| SI (1) | SI3914600T1 (https=) |
| WO (1) | WO2020152132A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022258622A1 (en) | 2021-06-07 | 2022-12-15 | Ares Trading S.A. | Combination treatment of cancer |
| CN119173276A (zh) | 2022-04-13 | 2024-12-20 | 吉利德科学公司 | 用于治疗表达Trop-2的癌症的组合疗法 |
| KR20250048043A (ko) | 2022-08-02 | 2025-04-07 | 메르크 파텐트 게엠베하 | (S)-7-옥사-2-아자-스피로[4.5]데칸-2-카르복실산 [7-(3,6-디히드로-2H-피란-4-일)-4-메톡시-티아졸로[4,5-c]피리딘-2-일]-아미드의 신규의 결정질 형태 및 이의 공-결정 형태 |
| CN116217511B (zh) * | 2023-03-22 | 2024-04-19 | 沈阳药科大学 | 一种双靶点化合物及其制备方法和在制备sEH抑制剂与PPARs激动剂中的应用 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007505851A (ja) | 2003-09-19 | 2007-03-15 | エフ．ホフマン−ラ ロシュ アーゲー | アデノシン受容体リガンドとしてのチアゾピリジン誘導体 |
| JP2007522765A (ja) | 2004-02-13 | 2007-08-09 | インターデイジタル テクノロジー コーポレーション | ＨＳ−ＳＣＣＨ（ＨｉｇｈＳｐｅｅｄＳｈａｒｅｄＣｏｎｔｒｏｌＣｈａｎｎｅｌ：高速共有制御チャンネル）の迅速な検出を提供する方法および装置 |
| JP2007528220A (ja) | 2004-03-09 | 2007-10-11 | ヨセフ ヴァイラン | 特に競技馬用の蹄のための機械的蹄鉄 |
| JP2007535887A (ja) | 2004-02-24 | 2007-12-06 | パテント−トロイハント−ゲゼルシヤフト フユール エレクトリツシエ グリユーラムペン ミツト ベシユレンクテル ハフツング | コンバータ向け制御回路 |
| JP7336434B2 (ja) | 2017-08-01 | 2023-08-31 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4125828A (en) | 1972-08-04 | 1978-11-14 | Med-El Inc. | Method and apparatus for automated classification and analysis of cells |
| US4207554A (en) | 1972-08-04 | 1980-06-10 | Med-El Inc. | Method and apparatus for automated classification and analysis of cells |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| US6291455B1 (en) | 1996-03-05 | 2001-09-18 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| AU1688599A (en) | 1998-01-05 | 1999-07-26 | Eisai Co. Ltd. | Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| US6841549B1 (en) | 1999-07-02 | 2005-01-11 | Eisai Co., Ltd. | Condensed imidazole compounds and a therapeutic agent for diabetes mellitus |
| NZ522074A (en) | 2000-05-31 | 2004-06-25 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| AU8181701A (en) * | 2000-06-21 | 2002-01-02 | Hoffmann La Roche | Benzothiazole derivatives |
| IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| CN1255392C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管生成抑制剂的秋水仙醇衍生物 |
| WO2004089942A2 (en) | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
| US6734179B2 (en) * | 2001-12-12 | 2004-05-11 | Hoffmann-La Roche Inc. | Benzothiazoles |
| EP1465634B1 (en) | 2001-12-12 | 2014-10-22 | The Government of the United States of America, as represented by the Secretary Department of Health and Human Services | Methods for using adenosine receptor inhibitors to enhance immune response and inflammation |
| EP1618108A2 (en) | 2003-04-09 | 2006-01-25 | Biogen Idec MA Inc. | Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosine receptor antagonists |
| JP4444290B2 (ja) | 2003-05-19 | 2010-03-31 | エフ．ホフマン−ラ ロシュ アーゲー | アデノシン受容体リガンドとしてのベンゾチアゾール誘導体 |
| CN1989139B (zh) | 2004-07-22 | 2010-05-12 | 弗·哈夫曼-拉罗切有限公司 | 苯并噻唑衍生物 |
| WO2014101120A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
| US11220492B2 (en) * | 2017-05-17 | 2022-01-11 | Arcus Biosciences, Inc. | Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders |
-
2020
- 2020-01-20 AR ARP200100134A patent/AR117844A1/es unknown
- 2020-01-21 BR BR112021014406A patent/BR112021014406A2/pt unknown
- 2020-01-21 RS RS20241147A patent/RS66038B1/sr unknown
- 2020-01-21 MX MX2021008510A patent/MX2021008510A/es unknown
- 2020-01-21 PL PL20700918.4T patent/PL3914600T3/pl unknown
- 2020-01-21 US US17/424,568 patent/US12344623B2/en active Active
- 2020-01-21 DK DK20700918.4T patent/DK3914600T3/da active
- 2020-01-21 AU AU2020211697A patent/AU2020211697B2/en active Active
- 2020-01-21 JP JP2021542335A patent/JP7600119B2/ja active Active
- 2020-01-21 SI SI202030510T patent/SI3914600T1/sl unknown
- 2020-01-21 ES ES20700918T patent/ES2992081T3/es active Active
- 2020-01-21 CA CA3127284A patent/CA3127284A1/en active Pending
- 2020-01-21 WO PCT/EP2020/051347 patent/WO2020152132A1/en not_active Ceased
- 2020-01-21 PT PT207009184T patent/PT3914600T/pt unknown
- 2020-01-21 HU HUE20700918A patent/HUE068968T2/hu unknown
- 2020-01-21 EP EP20700918.4A patent/EP3914600B1/en active Active
- 2020-01-21 HR HRP20241385TT patent/HRP20241385T1/hr unknown
- 2020-01-21 SG SG11202107858WA patent/SG11202107858WA/en unknown
- 2020-01-21 FI FIEP20700918.4T patent/FI3914600T3/fi active
- 2020-01-21 CN CN202080010474.8A patent/CN113939520B/zh active Active
- 2020-01-21 KR KR1020217026069A patent/KR102891741B1/ko active Active
- 2020-01-21 LT LTEPPCT/EP2020/051347T patent/LT3914600T/lt unknown
-
2021
- 2021-07-21 IL IL285024A patent/IL285024A/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007505851A (ja) | 2003-09-19 | 2007-03-15 | エフ．ホフマン−ラ ロシュ アーゲー | アデノシン受容体リガンドとしてのチアゾピリジン誘導体 |
| JP2007522765A (ja) | 2004-02-13 | 2007-08-09 | インターデイジタル テクノロジー コーポレーション | ＨＳ−ＳＣＣＨ（ＨｉｇｈＳｐｅｅｄＳｈａｒｅｄＣｏｎｔｒｏｌＣｈａｎｎｅｌ：高速共有制御チャンネル）の迅速な検出を提供する方法および装置 |
| JP2007535887A (ja) | 2004-02-24 | 2007-12-06 | パテント−トロイハント−ゲゼルシヤフト フユール エレクトリツシエ グリユーラムペン ミツト ベシユレンクテル ハフツング | コンバータ向け制御回路 |
| JP2007528220A (ja) | 2004-03-09 | 2007-10-11 | ヨセフ ヴァイラン | 特に競技馬用の蹄のための機械的蹄鉄 |
| JP7336434B2 (ja) | 2017-08-01 | 2023-08-31 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体 |
Also Published As
| Publication number | Publication date |
|---|---|
| DK3914600T3 (da) | 2024-10-07 |
| KR20210116572A (ko) | 2021-09-27 |
| IL285024A (en) | 2021-09-30 |
| SI3914600T1 (sl) | 2025-03-31 |
| ES2992081T3 (es) | 2024-12-09 |
| LT3914600T (lt) | 2024-12-27 |
| RS66038B1 (sr) | 2024-11-29 |
| CA3127284A1 (en) | 2020-07-30 |
| CN113939520A (zh) | 2022-01-14 |
| MX2021008510A (es) | 2021-09-21 |
| US20220119412A1 (en) | 2022-04-21 |
| CN113939520B (zh) | 2024-11-22 |
| AU2020211697A1 (en) | 2021-09-09 |
| KR102891741B1 (ko) | 2025-11-26 |
| WO2020152132A1 (en) | 2020-07-30 |
| HUE068968T2 (hu) | 2025-02-28 |
| EP3914600B1 (en) | 2024-08-07 |
| PL3914600T3 (pl) | 2024-12-23 |
| EP3914600A1 (en) | 2021-12-01 |
| JP2022524914A (ja) | 2022-05-11 |
| FI3914600T3 (fi) | 2024-10-31 |
| SG11202107858WA (en) | 2021-08-30 |
| US12344623B2 (en) | 2025-07-01 |
| AU2020211697B2 (en) | 2025-08-14 |
| PT3914600T (pt) | 2024-10-04 |
| BR112021014406A2 (pt) | 2021-12-07 |
| AR117844A1 (es) | 2021-09-01 |
| HRP20241385T1 (hr) | 2024-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7600119B2 (ja) | アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体 | |
| CN110997662B (zh) | 作为腺苷受体拮抗剂的苯并咪唑衍生物 | |
| JP7287951B2 (ja) | アデノシン受容体アンタゴニストとしてのキノキサリン誘導体 | |
| TWI850199B (zh) | 做為腺苷受體拮抗劑之噻唑并吡啶衍生物 | |
| US20250049814A1 (en) | 5-azaindazole derivatives as adenosine receptor antagonists | |
| RU2810114C2 (ru) | Тиазолопиридиновые производные в качестве антагонистов аденозиновых рецепторов | |
| RU2790011C2 (ru) | Тиазолопиридиновые производные в качестве антагонистов аденозиновых рецепторов | |
| RU2781429C2 (ru) | Бензимидазольные производные в качестве антагонистов аденозиновых рецепторов | |
| RU2791168C1 (ru) | Хиноксалиновые производные в качестве антагонистов аденозиновых рецепторов | |
| WO2024099898A1 (en) | Substituted bi-and tricyclic hset inhibitors | |
| BR112020001978B1 (pt) | Derivados de tiazolopiridina como antagonistas de receptor de adenosina, seu processo de preparação e seu uso, preparação farmacêutica e seu processo de preparação, e kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220415 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20230120 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230120 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231204 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231212 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240312 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20240312 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240312 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240517 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240815 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20241105 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20241204 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7600119 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |